Tab Application Banner
  • Users Online: 279
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
REVIEW ARTICLE
Year : 2011  |  Volume : 6  |  Issue : 6  |  Page : 99-112

Infections associated with the use of biologic response modifiers in rheumatic diseases: a critical appraisal


1 Sr. Consultant Rheumatologist, 'A & R Clinical for Arthritis & Rheumatism' and Department of Rheumatology, ISIC Superspeciality Hospital, Vasant Kunj, New Delhi-110070
2 Division of Rheumatology, Toronto Western Hospital, 399 Bathurst Street, Toronto, Canada

Correspondence Address:
Nigil Haroon
Division of Rheumatology, Toronto Western Hospital, 399 Bathurst Street, Toronto, Canada

Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Patients with autoimmune inflammatory rheumatic disorders have a higher incidence of infections indicative of inher- ent immunosuppressed state related to the disease activity. The latter is made worse by DMARD, including steroids that are universally used to treat these disorders. The problem has been compounded further with increasing world- wide use of biological response modifiers (BRMs or biologics) for the treatment of systemic inflammatory rheumatic diseases, especially rheumatoid arthritis (RA). To some extent, this was predicted considering that most BRM used in rheumatology practice specifically target molecules involved in the functioning of innate or adaptive immune sys- tem of the host defense system. The adverse effects of BRM, however, need to be balanced against their remarkable efficacy in disease control. BRM are highly effective drugs that have revolutionized the treatment of these diseases. In this paper the current status of infection with the use of BRM in rheumatic diseases is discussed. On balance, biologics seem to be safe drugs with acceptable range of drug-related infections. The preponderance of data indicates that TNF inhibitors (iTNF) are associated with a small increased risk of serious bacterial infections. The most common associated infections are urinary tract infection, pneumonia, upper respiratory infection, and soft- tissue/skin infections. Available data strongly suggest an increased risk of tuberculosis-flare with iTNF medications, especially the monoclonal drugs and has been discussed separately. Though sparse and grossly limited, the Indian data has been reviewed. Stringent screening is required for TB and other community infections prior to initiating BRM.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed484    
    Printed7    
    Emailed0    
    PDF Downloaded34    
    Comments [Add]    

Recommend this journal